Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 April 2023 | Story Nonkululeko Nxumalo | Photo Supplied
TSOHO ‘The Awakening’
TSOHO ‘The Awakening’ – available at the UFS library.


In celebration of linguistic diversity and the power of creative expression, the University of the Free State (UFS) African Languages Press and the Academy for Multilingualism launched a new seminal book, TSOHO 'The Awakening', on 14 April 2023.

This anthology of poetry and short stories stems from the first cohort of authors who participated in the Creative Writing Multilingual Hub masterclasses held in July 2022 with Ntabiseng Jafta, Publishing Coordinator at the African Languages Press; Dr Jerry Mofokeng wa Makgetha, author and award-winning South African actor; Dr Mathene Mahanke, Free State Head of Provincial Language Services; and Dr Elias Malete, Senior Lecturer and Academic Head in the Department of African Languages

What sets this collection apart is that the students took pride in expressing themselves in not just one, but seven indigenous South African languages, showcasing the rich tapestry of cultures and traditions that make up this vibrant nation.

“We hope that this launch will not only inspire you to read, but also to write, especially in indigenous languages. In that way, we can preserve, promote, and develop our African languages,” Dina Mashiyane: Head Librarian in the UFS Library and Information Services (LIS), highlighted during her welcoming speech.

In her message of support, the words of the Director of the Academy for Multilingualism, Dr Nomalungelo Ngubane, echoed the significance of this book, not just as a celebration of creativity and multilingualism, but also as a seed of inspiration that has the potential to grow. “Other young writers will look at you and take that initiative as well, standing proud in their languages,” she added.

Bangodi ‘The Authors’

The authors, whose names are a testament to their unique identities and backgrounds, include Ontlametse Manana Mothobi, Judith Tladi, Paseka Mathonsi, Langelihle Button, Celuxolo Mthembu, Kesaobaka Ncubuka, Modiehi Motseko, Ciliciah Chagane, Siphilangekhosi Dlamini, Tshegofatso Sello Kitso, Tlotlisang David Mhlambiso, and Balisa Nqambuza. These diverse voices are woven together in this anthology to create a symphony of words that will resonate with readers of all backgrounds.

Augmented Reality Feature

TSOHO is not just any ordinary book. With assistance from Thuthukani Ndlovu, augmented reality developer and alumnus of the UFS, this anthology is an innovative work that pushes the boundaries of traditional literature, embracing the digital age with an augmented reality feature that brings the pages to life.
 
Through the Artivive app, readers can experience a digital journey, where images in the book come alive with audio recitals in vernac. This unique fusion of traditional storytelling and modern technology is a testament to the innovative thinking of the African Languages Press, which seeks to promote and preserve indigenous languages across all spheres of human interaction.

Inspiration behind the title

When asked about the inspiration behind the title, Jafta had this to say, “We wanted them to wake up to themselves. To know that they have it within them to express and write in many languages. We have languages, they’re ours and they’re engraved within our DNA. We just wanted them to go into an experience of realisation, of discovery, but mostly to have that moment of awakening to say I too can. That’s why I came up with this title.”

Jafta also mentioned that there would be future cohorts, “This is our first offering, there are still more to come. We’re going to have our second cohort, so be on the lookout, they will be advertising for the next one,” she said.
 
The book can be found at the UFS library and will soon be available at Exclusive Books. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept